Edwards Backs Limits on Heart Valve to Assure U.S. Coverage
This article is for subscribers only.
Edwards Lifesciences Corp. accepted restrictions on its Sapien heart valve that may cut U.S. sales $100 million in 2015 in exchange for guarantees Medicare will pay for its use in patients too sick for chest-opening surgery.
The company backed most limits sought by the Society of Thoracic Surgeons in Chicago and the American College of Cardiology in Washington as it awaits regulatory approval to sell the first less-invasive heart valve in the U.S.